Strict eligibility criteria for renal denervation trials, particularly age and diastolic blood pressure limitations, result in a very low prevalence of eligible Japanese outpatients with treatment-resistant hypertension, highlighting significant recruitment challenges.
Answers are grounded in this paper and cite their sources.
Strict eligibility criteria exclude nearly all real-world patients from renal denervation trials; leaves open whether broader criteria would improve enrollment and generalizability.
(RHT-R). We investigated the proportion of patients in each category. We also investigated HT patients (1,423 cases) who were enrolled in the Chikushi Anti-Hypertension Trial (CHAT), a research network that includes general practitioners. Results Eleven patients (1.1%) with RHT-S and 18 patients (1.8%) with RHT-R were identified. After the exclusion of patients with secondary HT and a diastolic blood pressure (DBP) of <90 mmHg (applied in REQUIRE), 5 patients (0.5%) with RHT-S and 4 patients (0.4%) with RHT-R remained. In the analysis of the CHAT study, only 2 (0.1%) patients with RHT-R remained. Conclusion The number of eligible patients in the REQUIRE trial was decreased, largely due to the strict age restriction and the new DBP limitation. The prevalence of eligible patients in REQUIRE was estimated to be approximately 0.5 to 0.8 times that in SH-J. Since patient enrollment will be difficult, drastic measures may be required to recruit eligible patients.
No takes yet. Share an insight, caveat, or question.
Okamura et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: